介素-1受体对手基因多态性和冠状动脉疾病
S E Francis1, N J Camp, R M Dewberry
1Division of Clinical Sciences, University of Sheffield, UK.
Circulation
|February 23, 1999
概括
介素-1受体对手 (IL-1RN) *2基因变异与单血管冠状动脉疾病 (SVD) 有关. 这种遗传关联在单血管和多血管冠状动脉疾病之间存在差异,突出了冠状动脉疾病进展中的特定遗传因素.
科学领域:
- 免疫遗传学 免疫遗传学
- 心血管疾病遗传学 心血管疾病遗传学
- 炎症病理学 炎症病理学
背景情况:
- 细胞因子基因变异有助于炎症病理.
- 研究了互白素 (IL) -1 集群和瘤坏死因子 (TNF) -α基因的等位基因频率.
- 在健康捐赠者,冠状动脉正常患者,单血管疾病 (SVD) 和多血管疾病 (MVD) 中比较基因变异.
研究的目的:
- 确定特定细胞因子基因多态和冠状动脉疾病 (CAD) 之间的关联.
- 为了调查IL-1集群和TNF-alpha基因的等位基因频率是否在CAD患者组和对照组之间存在差异.
- 探索从单血管到多血管冠状动脉疾病的进展中的潜在遗传差异.
主要方法:
- 在谢菲尔德和伦敦人群中对IL-1A,IL-1B,IL-1RN和TNFA基因多态的基因定型.
- 在健康对照组,患者对照组,SVD和MVD组中分析等位基因和基因型频率.
- 统计测试不同患者队伍中遗传变异的显著关联和趋势.
主要成果:
- 与对照组相比,在单血管冠状动脉疾病 (SVD) 患者中,IL-1RN*2等位基因显著过高 (34%对23%).
- 在谢菲尔德人群中,IL-1RN*2类同位素与SVD有显著的关联 (P=0.0036).
- 在谢菲尔德和伦敦人群中观察到IL-1RN*2与SVD相关的显著趋势 (P=0.0024),以及SVD和MVD人群之间的显著差异 (P=0.0007).
结论:
- IL-1RN*2多态性与单血管冠状动脉疾病 (SVD) 有显著的关联.
- 在SVD和多血管冠状动脉疾病 (MVD) 之间存在着独特的遗传关联模式.
- 这些发现表明,特定的遗传倾向会影响冠状动脉疾病的发展和严重程度.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...